I don't believe that the Smartcells property is comparable to the OPXA islet cell technology under development with Novartis except from one angle; Major labs are keenly aware of the development status of these preclinical therapies and organize their options accordingly. I think folks can draw their own conclusions about Neil Warma's background and the progress to-date with Novartis. Neil has a sound say/do ratio and I am hard pressed to think of a developmental lab with a more conservative communications strategy. These conditions favor the DD-oriented investor.
Market Data 
Markets 
AI
